Ambrisentan

Generic Name
Ambrisentan
Brand Names
Letairis, Volibris, Ambrisentan Mylan
Drug Type
Small Molecule
Chemical Formula
C22H22N2O4
CAS Number
177036-94-1
Unique Ingredient Identifier
HW6NV07QEC
Background

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with ...

Indication

用于治疗肺动脉高血压(PAH)。

Associated Conditions
Pulmonary arterial hypertension WHO functional class I
Associated Therapies
-
Clinical Trials
Related News

Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529

Phase 2
Completed
Conditions
Hypertension, Pulmonary
Interventions
Drug: Ambrisentan
First Posted Date
2011-04-27
Last Posted Date
2022-12-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
38
Registration Number
NCT01342952
Locations
🇪🇸

GSK Investigational Site, Madrid, Spain

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

First Posted Date
2011-04-19
Last Posted Date
2022-01-18
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
30
Registration Number
NCT01338636
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension

Phase 4
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: ambrisentan
First Posted Date
2011-04-06
Last Posted Date
2014-08-11
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
32
Registration Number
NCT01330108
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Phase 3
Completed
Conditions
Portopulmonary Hypertension
Interventions
Drug: Ambrisentan
First Posted Date
2010-10-19
Last Posted Date
2021-01-12
Lead Sponsor
Tufts Medical Center
Target Recruit Count
30
Registration Number
NCT01224210
Locations
🇺🇸

UCSD Medical Center, La Jolla, California, United States

🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

🇺🇸

The Ohio State University Medical Center, Columbus, Ohio, United States

and more 3 locations

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Phase 3
Completed
Conditions
Hypertension, Pulmonary
Interventions
Drug: ambrisentan
Drug: tadalafil
First Posted Date
2010-08-09
Last Posted Date
2017-09-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
610
Registration Number
NCT01178073
Locations
🇬🇧

GSK Investigational Site, Sheffield, United Kingdom

Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

Not Applicable
Completed
Conditions
Systemic Sclerosis
Scleroderma
Interventions
Drug: Ambrisentan
First Posted Date
2010-03-26
Last Posted Date
2018-11-29
Lead Sponsor
University of Pennsylvania
Target Recruit Count
15
Registration Number
NCT01093885
Locations
🇺🇸

University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

Not Applicable
Completed
Conditions
Ischemia
Interventions
Drug: ambrisentan
First Posted Date
2010-02-22
Last Posted Date
2013-05-03
Lead Sponsor
Soumya Chatterjee
Target Recruit Count
20
Registration Number
NCT01072669
Locations
🇺🇸

Nilanjana Bose, Md, Cleveland, Ohio, United States

Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan

First Posted Date
2010-01-20
Last Posted Date
2020-11-02
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
12
Registration Number
NCT01051960
Locations
🇺🇸

David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, United States

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

First Posted Date
2009-04-09
Last Posted Date
2014-05-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
40
Registration Number
NCT00879229
Locations
🇺🇸

Mayo Clinic Arizona, Scottsdale, Arizona, United States

🇦🇹

Medizinische Universität Graz, Graz, Austria

🇦🇹

Universitatsklinikum Innsbruck, Innsbruck, Austria

and more 82 locations

Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension

Phase 2
Completed
Conditions
Pulmonary Hypertension
Sarcoidosis
Interventions
Drug: Ambrisentan
First Posted Date
2009-02-26
Last Posted Date
2018-08-02
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
16
Registration Number
NCT00851929
Locations
🇺🇸

University of North Carolina Medical Center, Chapel Hill, North Carolina, United States

🇺🇸

Medical Univerrsity of South Carolina, Charleston, South Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy